These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 3530584)

  • 1. Clinical pharmacokinetics of dapsone.
    Zuidema J; Hilbers-Modderman ES; Merkus FW
    Clin Pharmacokinet; 1986; 11(4):299-315. PubMed ID: 3530584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetic considerations in the treatment of patients with leprosy.
    Venkatesan K
    Clin Pharmacokinet; 1989 Jun; 16(6):365-86. PubMed ID: 2661102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of dapsone and acetylated dapsone in serum and saliva.
    Lammintausta K; Kangas L; Lammintausta R
    Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):159-63. PubMed ID: 447435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylation polymorphism of dapsone in a Japanese population.
    Horai Y; Ishizaki T
    Br J Clin Pharmacol; 1988 Apr; 25(4):487-94. PubMed ID: 3382590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapsone in saliva and plasma of man.
    Peters JH; Murray JF; Gordon GR; Gelber RH
    Pharmacology; 1981; 22(3):162-71. PubMed ID: 7208598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.
    Ahmad RA; Rogers HJ
    Br J Clin Pharmacol; 1980 Nov; 10(5):519-24. PubMed ID: 7437265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylation phenotyping with dapsone in a mainland Chinese population.
    Horai Y; Zhou HH; Zhang LM; Ishizaki T
    Br J Clin Pharmacol; 1988 Jan; 25(1):81-7. PubMed ID: 3370194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylation phenotyping using dapsone in a Jordanian population.
    Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM
    Br J Clin Pharmacol; 1991 Sep; 32(3):289-93. PubMed ID: 1777365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic observations on dapsone in dermatitis herpetiformis.
    Swain AF; Ahmad RA; Rogers HJ; Leonard JN; Fry L
    Br J Dermatol; 1983 Jan; 108(1):91-8. PubMed ID: 6821646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous estimation of serum concentrations of dapsone, monoacetyldapsone, and pyrimethamine in Chinese men on maloprim for malaria prophylaxis using reversed-phase high performance liquid chromatography.
    Lee HS; Ti TY; Lee PS; Yap CL
    Ther Drug Monit; 1985; 7(4):415-20. PubMed ID: 3909534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of proguanil on the pharmacokinetics of dapsone in healthy volunteers.
    Edstein MD; Rieckmann KH
    Chemotherapy; 1993; 39(4):235-41. PubMed ID: 8325124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.
    Edstein MD; Rieckmann KH; Veenendaal JR
    Br J Clin Pharmacol; 1990 Aug; 30(2):259-65. PubMed ID: 2206787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral activated charcoal and dapsone elimination.
    Neuvonen PJ; Elonen E; Mattila MJ
    Clin Pharmacol Ther; 1980 Jun; 27(6):823-7. PubMed ID: 7379451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The disposition of dapsone and monoacetyldapsone in the dog (38516).
    Peters JH; Gordon R; Biggs JT; Levy L
    Proc Soc Exp Biol Med; 1975 Jan; 148(1):251-5. PubMed ID: 1129265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of dapsone and monoacetyldapsone in rats.
    Gordon GR; Peters JH; Ghoul DC; Murray JF; Levy L; Biggs JT
    Proc Soc Exp Biol Med; 1975 Nov; 150(2):485-92. PubMed ID: 1208566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma dapsone and its metabolite monoacetyldapsone levels in leprotic patients.
    Garg SK; Kumar B; Bakaya V; Lal R; Shukla VK; Kaur S
    Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):552-4. PubMed ID: 3243659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acedapsone treatment of leprosy patients: response versus drug disposition.
    Peters JH; Murray JF; Gordon GR; Levy L; Russell DA; Scott GC; Vincin DR; Shepard CC
    Am J Trop Med Hyg; 1977 Jan; 26(1):127-36. PubMed ID: 842774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs.
    Palamanda JR; Hickman D; Ward A; Sim E; Romkes-Sparks M; Unadkat JD
    Drug Metab Dispos; 1995 Apr; 23(4):473-7. PubMed ID: 7600914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of dapsone after oral administration to healthy volunteers.
    Pieters FA; Zuidema J
    Br J Clin Pharmacol; 1986 Oct; 22(4):491-4. PubMed ID: 3768260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A field trial among leprosy patients in Nigeria with depot injections of dapsone and monoacetyldapsone.
    Pieters FA; Woonink F; Zuidema J
    Int J Lepr Other Mycobact Dis; 1988 Mar; 56(1):10-20. PubMed ID: 3373080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.